RBC expects many years of further growth for pharmaceutical CDMOs
29/06/2021 07:48
** RBC sees many years of further growth for pharmaceutical
CDMOs (contract development and manufacturing organizations) as
it notes their resilience and upturn through the coronavirus
pandemic
** It initiates the coverage of Switzerland-based Siegfried
SFZN.S with an "outperform" rating and Lonza LONN.S with a
"sector perform" rating
** The broker expects coronavirus vaccine contracts (Moderna
MRNA.O for Lonza and Pfizer PFE.N -BioNTec 22UAy.DE , Novavax
NVAX.O for Siegfried) to provide a boost to near-term growth
to both companies
** RBC also reiterates its "outperform" ratings on
U.S.-based Catalent CTLT.N and Avid Bioservices CDMO.O ,
Germany's Evotec EVTG.DE and Britain's Oxford Biomedica
OXB.L , despite significant recent share price outperformance
(Reporting by Veronica Snoj)
((veronica.snoj@thomsonreuters.com; +48 58 769 65 89;))